Hospital del Mar

OCS-05, a neuroprotective therapy, showed positive safety and efficacy in the Phase 2 ACUITY trial for acute optic neuritis, achieving significant improvements in retinal thickness and visual function. It received FDA IND clearance, enabling U.S. clinical development. Oculis plans further studies and explores its potential in other neuro-ophthalmic conditions.

Natera's SAGITTARIUS trial, using Signatera for early-stage colon cancer, aims to enroll 700-900 patients to evaluate personalized adjuvant treatments. Signatera-positive patients may receive genotype-guided therapy or standard chemotherapy, while negative patients may de-escalate to observation or single-agent capecitabine. The trial involves 26 clinical centers in Italy, Spain, and Germany, with collaborations across Europe.